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ABSTRACT 
 
Background  
Manganese is an essential micronutrient for humans, but excessive levels are harmful. 
Manganese neurotoxicity is associated with parkinsonism and the associated motor deficits can 
affect an individual’s daily activities and quality of life (QoL) in manganese–exposed persons.  
 
Objectives 
In this study, we sought to investigate the associations between manganese, parkinsonism and 
QoL in South African manganese mine workers, in the period 2010–2014. 
 
Methods 
This was a secondary analysis of data from 418 South African manganese mine workers already 
recruited into a prospective study of the association between Mn mining exposure and 
parkinsonism. Parkinsonism, the primary outcome, was defined as a Unified Parkinson’s Disease 
Rating Scale motor subsection part 3 score (UPDRS-3) ≥15. The 39–item Parkinson’s Disease 
Questionnaire (PDQ-39) was used to assess miners’ health status or QoL, the secondary 
outcome. Cumulative manganese exposure in mg/m3-year (measured as inhalable dust) was 
estimated using an exposure matrix from participants’ job histories. We used Mann-Whitney and 
Pearson’s Chi-Square tests to compare participants’ parkinsonism status with regard to baseline 
continuous and categorical characteristics. Multiple linear and logistic regression modeling was 
used to quantify associations.  
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Results 
The mean age of the manganese mine workers was 41.5 years (SD=11.9); 97.6% were male. 
Average manganese exposure was estimated as 3.7 mg/m3-years (SD=5.8) at baseline with mean 
duration of 13.5 years (SD=11.7). The prevalence of parkinsonism was 29.4%. Participants’ 
characteristics, stratified by parkinsonism status, differed significantly by age, education, and 
comorbid disease. Parkinsonism prevalence decreased significantly with increasing miners’ 
education status, p=0.029 and was higher (36.4% vs 25.9%, p=0.042) in those with 
comorbidities. Parkinsonism participants were generally older (mean age 45.3 vs 39.6, 
p<0.0001). QoL sub-scores and total scaled PDQ-39 score means were higher in mine workers 
with parkinsonism compared to those without. We found no evidence of a monotonic dose-
response relationship between cumulative manganese exposure and parkinsonism. Similarly, 
there was no statistically significant association between QoL and cumulative manganese 
exposure. Being aged 40 years or older was an independent risk factor for having parkinsonism 
(OR=2.11, 95% CI: 1.18, 3.78). Parkinsonism (β=0.63, p=0.004) and age (β= -0.48, p=0.031) 
were strong predictors of QoL. 
 
Conclusion 
We found a strong association between parkinsonism and QoL in manganese mine workers, 
confirming previous reports in manganese–exposed welders. There was no evidence of an 
association between parkinsonism and manganese exposure. The lack of a monotonic dose–
response relationship between parkinsonism and manganese exposure may be due to the healthy 
worker survivor effect, a non-linear relationship, or exposure misclassification.    
 
 vi 
TABLE OF CONTENTS 
 
DECLARATION ............................................................................................................................. i 
DEDICATION ................................................................................................................................ ii 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
ABSTRACT ................................................................................................................................... iv 
LIST OF FIGURES ..................................................................................................................... viii 
LIST OF TABLES ......................................................................................................................... ix 
ABBREVIATIONS ........................................................................................................................ x 
CHAPTER 1: INTRODUCTION ................................................................................................... 1 
1.1 Background ...................................................................................................................... 1 
1.2 Literature Review ............................................................................................................. 4 
1.2.1 Manganese Toxicity .................................................................................................. 4 
1.2.2 Low and High Levels of Manganese ........................................................................ 5 
1.2.3 Manganese Neurotoxicity and Parkinsonism............................................................ 6 
1.2.4 Quality of Life (QoL)................................................................................................ 7 
1.3 Problem Statement ........................................................................................................... 8 
1.4 Justification .................................................................................................................... 10 
1.5 Study Aim ...................................................................................................................... 10 
1.6 Objectives ....................................................................................................................... 11 
CHAPTER 2: METHODS ............................................................................................................ 12 
2.1 Primary Study Methodology .......................................................................................... 12 
2.2 Secondary Data Analysis Methodology ......................................................................... 13 
2.2.1 Study Design ........................................................................................................... 13 
2.2.2 Study Site ................................................................................................................ 13 
2.2.3 Effect Size ............................................................................................................... 13 
2.2.4 Study Variables and Measurement ......................................................................... 14 
2.3 Data Management and Data Analysis ............................................................................ 17 
2.3.1 Data Management ................................................................................................... 17 
2.3.2 Statistical Analysis .................................................................................................. 17 
2.4 Ethical Considerations.................................................................................................... 19 
 
 
 vii 
CHAPTER 3: RESULTS .............................................................................................................. 20 
3.1 Selection of Study Participants for Analysis ..................................................................... 20 
3.2 Description of Study Participants ...................................................................................... 21 
3.3 Prevalence of Parkinsonism in Manganese Mine Workers ............................................... 23 
3.4 Quality of Life in Manganese Mine Workers .................................................................... 25 
3.5 Association between Manganese Exposure and Parkinsonism ......................................... 26 
3.6 Association between Manganese Exposure and Quality of Life ....................................... 28 
CHAPTER 4: DISCUSSION ........................................................................................................ 32 
4.1 Synopsis of Study Findings ............................................................................................... 32 
4.2 Prevalence of Parkinsonism in Manganese Mine Workers ............................................... 32 
4.3 Quality of Life in South African Manganese Mine Workers with Parkinsonism .............. 34 
4.4 Association between Manganese Exposure and Parkinsonism ......................................... 34 
4.5 Quality of Life Predictors .................................................................................................. 36 
4.6 Limitations ......................................................................................................................... 37 
4.7 Strengths ............................................................................................................................ 38 
4.8 Conclusion ......................................................................................................................... 38 
REFERENCES ............................................................................................................................. 39 
APPENDIX A: Complementary Study Tables ............................................................................. 46 
APPENDIX B: Plagiarism Declaration Form............................................................................... 47 
APPENDIX C: Human Research Ethics Clearance Certificate .................................................... 48 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
LIST OF FIGURES 
 
Figure 1: Exclusion process flow chart ....................................................................................................... 20 
Figure 3: Predicted margins estimates quantifying the effect of age on QoL ............................................. 30 
 
 
  
 
 ix 
LIST OF TABLES 
 
Table 1: Computing effect size for a two–sample proportions test ............................................................ 14 
Table 2: Potential confounding variables included in the analyses ............................................................ 16 
Table 3: Description of study participants (categorical variables, N=418) ................................................ 22 
Table 4: Description of study participants (continuous variables, N=418) ................................................ 23 
Table 5: Number and proportion of participants’ characteristics by parkinsonism status .......................... 24 
Table 6: Description of participants’ characteristics, by parkinsonism status ............................................ 25 
Table 7: Quality of life/health status in manganese mine workers, by parkinsonism status ....................... 26 
Table 8: Association between manganese exposure and parkinsonism (logistic regression model) .......... 27 
Table 9: Association between manganese exposure and QoL (multiple linear regression model) ............. 28 
Table 10: Margins estimates for QoL ......................................................................................................... 29 
Table 11: Association between duration of exposure and parkinsonism (logistic regression model) ........ 46 
Table 12: Association between duration of exposure and QoL (multiple linear regression model) ........... 46 
 
 
 
 
  
 
 x 
ABBREVIATIONS 
 
ADL Activities of Daily Living 
BMI Body Mass Index 
HEG Homogeneous Exposure Group 
OEL  Occupational Exposure Limit 
PD Parkinson Disease 
PDQ-39 39–item Parkinson Disease Questionnaire 
QoL Quality of Life 
SF-36 36–item Short Form Health Survey 
UPDRS-3 Unified Parkinson Disease Rating Scale motor subsection part 3 
 
 
  1 
CHAPTER 1: INTRODUCTION 
 
This chapter begins with a description of manganese, both as a trace element and a 
micronutrient, followed by an account of its neurotoxicity, how it links to parkinsonism, and a 
description of quality of life (QoL) in manganese–exposed individuals. The problem statement 
and justification of the study are described and the chapter concludes with the study aim, and 
objectives.  
 
1.1 Background 
Manganese is a trace element that is required throughout the life span of human beings. It is an 
abundant metal in the Earth’s crust, usually occurring with iron, and is naturally present in soil, 
rocks, and certain foods. Manganese reserves are found primarily in China, Ukraine, Australia, 
South Africa, and Gabon. However, 80% of the world’s manganese reserves are in South Africa 
(1-3). Manganese exists in both organic and inorganic forms. The main dietary sources of 
manganese (organic) include whole grains, nuts, tea, and green leaves (4-7). Primary industrial 
uses for inorganic manganese include i) additive in steel production and fuel oil, ii) an oxidant 
for bleaching, cleaning and disinfection, and iii) ingredient in various consumer products such as 
cosmetics, fireworks, and dry-cell batteries (8, 9).  
 
Manganese is an essential biological nutrient for all living organisms, serving both enzymatic 
and structural functions (10, 11). It plays a role in regulating and/or binding to numerous 
enzymes in the body, acting as both an enzyme activator (e.g. decarboxylases) and a constituent 
element for a number of important enzymes (12).  
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For example, manganese is a co-factor for manganese superoxide dismutase which is a key 
enzyme in the prevention of oxidative damage; it is also a required element in the urea cycle (8, 
9).  
 
While manganese is essential for life, prolonged or excessive exposure is harmful to humans. 
High levels of exposure can occur in occupational settings and, over the last decade or so , there 
has been  renewed interest in manganese toxicity in various work environments, given evidence 
of adverse health effects occurring at levels below regulatory thresholds (13). The potential for 
chronic exposure to high levels of manganese occurs specifically in workers exposed to welding 
fumes, manganese dust in manganese mines, and manganese smelter emissions (14).  
 
The source of overexposure to manganese is both environmental and occupational (14). In the 
general population, exposure is commonly through diet, air inhalation, contaminated water or 
soil, and contact with manganese-contaminated surfaces (8). In occupational settings, manganese 
exposure is predominantly through inhalation (15), which several studies have suggested is the 
most harmful route  (16, 17). Absorption of inhaled manganese into the central nervous system is 
reported to be 10 times greater than that absorbed orally (16, 17).  
 
The primary target of manganese neurotoxicity is the central nervous system; although cardiac, 
liver, foetal, reproductive and lung toxicity have also been noted (12). At very high levels, initial 
manganese toxicity symptoms are subtle, and include poor sleep, mood changes, changes in 
appetite, fatigue, and behavioural changes (18). These are usually insidious and can be 
progressive. 
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Evidence suggests that insufficient intake of manganese impairs organ function, contributes to 
bone deformities, retards growth, and causes birth defects, amongst other ailments (11, 16, 19), 
whereas high levels of manganese are toxic and lead to detrimental health effects (8, 13, 20, 21). 
The most common adverse health outcomes associated with excess levels of manganese 
exposure are motor and cognitive dysfunction (14, 17, 22).  
 
Classically, manganese neurotoxicity is associated with a severe movement disorder 
characterised by parkinsonism, dystonia, cognitive dysfunction, and behavioural disturbances 
(manganism)   (23-25). Parkinsonism is a movement disorder characterised by the presence of 
two or more of the cardinal clinical signs of Parkinson Disease (PD): rigidity, bradykinesia, rest 
tremor or postural instability (26, 27). 
 
Parkinsonism can result in significant motor deficits with loss of ambulation and independence. 
As the disease progresses, it is characterised by increasing motor disability and impairment, 
eventually affecting an individual’s daily activities and his/her expected or usual physical, 
mental and social health, referred to as health-related (28, 29). For instance, problems with 
movement can lead to limitations in performing self-care activities, depression, social seclusion, 
etc. In the workplace, poor health outcomes linked to exposure to manganese can affect job 
performance and worker safety. This could be in the form of decreased productivity, associated 
work absenteeism, job stress, and increased risk of occupational injuries (30).  
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1.2 Literature Review  
1.2.1 Manganese Toxicity  
It has long been established that the micronutrient, manganese, is also a neurotoxic substance 
(18). Occupational exposure, in particular, has been reported to cause manganese toxicity (31). 
Neurotoxicity results from the accumulation of manganese in the brain tissue (12). Several 
factors are associated with manganese toxic effects, including the duration, dose, and route of 
manganese exposure.  
 
In a blinded control study published in 1996 (32), assessing motor deficits in manganese-exposed 
persons, 27 Chilean miners exposed to manganese for more than five years, and 32 controls, 
were examined and compared. The manganese-exposed cohort was observed to frequently 
exhibit more action and resting tremor, and general difficulties in motor function than the control 
group. Subclinical changes in motor impairment were also noted in the miners. The authors 
concluded that chronic exposure to manganese in this cohort of asymptomatic miners resulted in 
detectable late-life movement abnormalities. Guilarte, in a 2013 review, reported that manganese 
intoxication produces motor dysfunction and cognitive deficits in both human (23) and non-
human subjects (33). In another study of a cohort of male smelter workers, published in 2015, 
poorer lung function was associated with cumulative exposure to manganese–containing dust 
(34). 
 
 
 
  5 
1.2.2 Low and High Levels of Manganese   
Mergler and Baldwin, reported that studies on early neurofunctional changes associated with 
manganese in the workplace collectively showed a significantly higher prevalence of hand 
unsteadiness and altered motor function at exposure levels below 5 mg/m3 of total manganese 
dust (14). Effects of low exposure levels of manganese (approximately 0.2 mg/m3) on the CNS 
were investigated in 138 manganese-exposed enamel production workers and 137 matched 
controls. No significant adverse effects on the nervous system function were reported. Subtle 
clinical symptoms such as headaches, weakness and sleep disturbances, instead, were noted (6, 
35). An epidemiological study comparing male subjects working in a manganese plant to 
matched controls noted that the prevalence of adverse health effects was higher among the 
exposed group than the controls (36). These health effects were related primarily to the CNS, and 
lungs. The study demonstrated that time-weighted average exposure to manganese of about 1 
mg/m3 may still lead to the occurrence of preclinical adverse effects in some workers exposed 
for a period of less than 20 years. Cited among neurological signs in workers occupationally 
exposed to low manganese levels (0.07 to 0.97 mg/m3) were: lower cognitive flexibility levels, 
poorer hand steadiness, postural stability, and prolonged reaction time (8).  
 
Inconsistent findings, however, have been reported in two major South African studies cross-
sectionally investigating manganese associated nervous system effects in persons occupationally 
exposed. These concluded that persons exposed within the exposure ranges studied were unlikely 
to have a subclinical neurotoxicity problem. The associations observed were more likely to be 
due to chance.  
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In the one analysis, 489 blue and white-collar manganese mine workers exposed to an average  
0.21 mg/m3 of inhalable manganese dust were studied (37). In the other study, 509 production 
workers at a manganese smelter and 67 external controls were equally investigated. Average 
intensity exposure levels ranged from near 0 (0.06 mg/m3) for external controls to 5.08 mg/m3 
for inhalable manganese dust in the latter study (38).  
 
Manganese intoxication, as manganism was also noted from epidemiological studies conducted 
in occupational groups (such as manganese miners and steel manufacturing workers) chronically 
exposed to high levels of manganese. These cases of clinical neurotoxicity were typically 
observed in workers exposed to levels higher than 5 mg/m3 (6). The United States Agency for 
Toxic Substances and Disease Registry (ATSDR) documented that workplace associated 
exposure levels ranging from about 2 to 22 mg/m3, can result in acute, and potentially disabling, 
neurological effects (8).  
 
1.2.3 Manganese Neurotoxicity and Parkinsonism 
Reports on parkinsonism related to manganese exposure have focused on manganese 
neurotoxicity and welding as potential risk factors. Chronic inhalation of high levels of 
manganese, especially in occupational settings, has been linked to a syndrome comprising 
neuropsychological disturbances, parkinsonism and cognitive deficits (33). Occupational 
manganese-induced parkinsonism will sometimes manifest as manganism, a degenerative 
neurologic syndrome (25).  
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A recent (2016) study investigating the progression of parkinsonism was carried out in 886 
welders with a mean duration of exposure to manganese of 4.2 years (24). This longitudinal 
analysis revealed Mn-dose dependent progressive parkinsonism. Prolonged manganese exposure 
also produces gradual psychological symptoms such as hallucinations, sleep disturbances, mood 
changes, psychosis, euphoria, and aggressiveness (33).  
 
1.2.4 Quality of Life (QoL) 
Neurotoxicity from occupational exposure to manganese from welding has been shown to be 
associated with parkinsonism, and the resulting motor deficits can affect an individual’s daily 
activities and QoL (30). Manganese neurotoxicity can be a contributing factor to the slow 
deterioration of an individual’s health status or QoL over time. That is, health might 
progressively deteriorate with increasing manganese exposure. The association between 
neurologic impairments and changes in worker health status has been investigated in only a few 
studies. 
 
Standardised tools can be employed to determine the general well-being of subjects (30). The      
39-item Parkinson Disease Questionnaire (PDQ-39) is one such health status questionnaire 
commonly used to assess the effect of parkinsonism on health status or QoL (30). It comprises 
39 questions measuring eight QoL dimensions: mobility, activities of daily living (ADL), body 
discomfort, emotional well-being, social support, stigma, communication, and cognition (28, 39). 
All questions have five scoring options ‘0 to 4’ (a likert scale), corresponding to ‘never’, 
‘occasionally’, ‘sometimes’, ‘often’, and ‘always/cannot do at all’.  
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The 36-item Short Form Health Survey (SF-36) is another commonly used tool to assess 
peoples’ health status (40). The SF-36 tool can be applied to varied areas (clinical practice, 
research, general population surveys), and for patients suffering from different diseases. It is 
composed of 36 items corresponding to eight dimensions of health: mental health, vitality, 
general health, role-physical, bodily pain, social function, physical functioning, and role-
emotional. Higher values in the SF-36 questionnaire indicate better health status.  
 
Harris (2011), showed that welders with parkinsonism had poorer QoL or health status than 
those without parkinsonism across all QoL dimension sub-scores (30). In this study, the PDQ-39 
was administered to examine the effects of parkinsonism on health status in welding–exposed 
workers. Another study conducted in Shanghai, China (2014) used the 36-item Short Form 
Health Survey (SF-36) to assess QoL in 301 male welders and 305 non-dust exposed male 
workers (40). The SF-36 health status dimensions were significantly worse in the welders than in 
the controls. A more recent (2015) study in 275 Ohio residents reported that air manganese 
concentrations were significantly associated with poor mental health and poor physical health, 
suggesting that environmental manganese exposure may also adversely affect QoL (41).  
 
1.3 Problem Statement 
Numerous authors have documented that neurotoxicity as a result of high or prolonged 
manganese exposure is a concern in some occupational settings. Manganese exposure occurs 
mainly during the mining and the smelting of ore (42), but there have also been reports of 
manganese exposure in welders.  
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Exposure to manganese has been associated with motor dysfunction, including chronic and 
progressive parkinsonism, as well as poor health status. However, epidemiological evidence to 
quantify these findings in manganese mining and smelting is limited. 
 
Generally, Africa’s contribution to neuroscience research is limited (43). Although parkinsonism 
is a common health problem globally, little is known about its prevalence or epidemiology in 
Africa. Most research on the health effects of manganese has established that excess manganese 
exposure can result in clinical and/or subclinical neurologic impairments, disability, and/or 
diminishing QoL (44, 45). These issues have received little attention in Africa, and even 
globally, there is limited research evaluating the chronic effects of low levels of manganese 
exposure.  
 
In addition, the threshold level for manganese exposure has not been tested with regard to 
adverse health effects (6, 8).  Although policies exist in some countries (including South Africa) 
to regulate manganese exposure in occupational settings, reports of manganese neurotoxicity 
continue (12). The existing occupational exposure limit (OEL) on  manganese dust and 
compounds (5 mg/m3) published in the 1995 South African Regulations for Hazardous Chemical 
Substances was last updated in 2008 and might, therefore, be out of date and no longer 
applicable (46). An OEL is the level to which workers are exposed during their working career 
that should not cause any adverse health effects to them or their offspring (46).  
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1.4 Justification 
The health effects of manganese exposure in the modern mining sector is under–researched. This 
study presents an opportunity to expand on the neurological research gap in the African context. 
South Africa accounts for more than 80% of the world’s known manganese resources, occurring 
predominately in the Northern Cape Province (1, 47), providing a good setting for the study. In 
2016, the South African manganese mining industry employed around 7 000 workers (48). Given 
the potentially serious consequences of high or prolonged exposure to manganese, viz., chronic 
neurologic disorders, it is important to better understand the relationships between manganese 
exposure, neurological effects, and QoL in manganese mine workers in South Africa. 
 
Demonstrating the associations between manganese exposure, parkinsonism and QoL may have 
important occupational, legislative, social and clinical implications, and could have significant 
repercussions for worker safety and performance (30).  
 
The threshold exposure level of manganese for the development of neurobehavioural or 
subclinical neurological effects has not been established (6). As such, this research sought to 
advance new knowledge to provide guidance for regulating OELs in manganese mining and 
enhancing health prevention strategies.  
 
1.5 Study Aim 
The aim of the study was to investigate the association between manganese exposure, 
parkinsonism, and quality of life in manganese–exposed mine workers in South Africa. 
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1.6 Objectives 
1. To estimate the prevalence of parkinsonism in a cohort of manganese-exposed mine workers 
in South Africa.  
2. To describe quality of life in those mine workers with and without parkinsonism.   
3. To determine the association between manganese exposure and parkinsonism among the 
manganese mine workers.   
4. To determine the association between manganese exposure and quality of life among the 
manganese mine workers.   
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CHAPTER 2: METHODS 
 
This chapter describes, in detail, the methods used in the analysis of the data, and includes a 
description of the study design, study site, study population, power calculations, the study 
variables and their measurement, and data management and analyses. Ethical considerations for 
this study are also addressed. 
 
2.1 Primary Study Methodology  
A prospective cohort study was implemented in 2010, comprising 418 manganese mine workers 
from four manganese mine shafts and an open pit located in the Northern Cape Province, South 
Africa: Mamatwan (open pit); and Wessels, Gloria, Nchwaning 2 and Nchwaning 3 
(underground). The aim of the study was to examine the association between manganese 
exposure and the signs and symptoms of parkinsonism. All active workers from the five 
worksites were eligible to participate in the study. The participating mine workers were followed 
up annually, for a period of five years.  
 
Data were collected using three main data collection instruments: a) Unified Parkinson Disease 
Rating Scale motor subsection part 3 (UPDRS-3), a valid and reliable clinical tool for assessing 
PD (49); b) PD symptom questionnaire, a short, but specific and sensitive tool for identifying 
individuals with symptoms of parkinsonism (50); and c) PDQ-39 questionnaire a health status 
and health–related QoL questionnaire – a self-administered, validated questionnaire with 
acceptable levels of test-retest and internal consistency reliability in PD respondents (39).  
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Additional data were extracted from employee annual medical examinations and human 
resources files. Participants’ demographic, behavioural (smoking, alcohol use), clinical and job 
history information were also collected using a structured questionnaire.   
 
2.2 Secondary Data Analysis Methodology  
2.2.1 Study Design 
This study used a cross-sectional study design in the analysis of 418 manganese mine worker 
characteristics at baseline exam, using the data prospectively collected in the primary study of 
parkinsonism in South African manganese miner workers, conducted in 2010-2014. 
 
2.2.2 Study Site 
Study participants were recruited from four manganese mine shafts and an open pit located in the 
Northern Cape Province, South Africa.  
 
2.2.3 Effect Size  
We computed the study’s effect size using a two-sample proportions test. The significance level 
was set at 0.05. Given that the proportion of participants without parkinsonism was 0.71 and 
using a power of 0.80, the smallest detectable difference is –0.1308, with a corresponding 
proportion value of 0.58 [see Table 1].  
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Table 1: Computing effect size for a two–sample proportions test 
Stata command: “power twoproportions 0.71, test(chi2) power(0.8) n(418) direction(lower)” 
Ho: p2 = p1 versus Ha: p2! = p1; p2 < p1   
Study parameters:   
alpha 0.0500 
power 0.8000 
N 418 
N per group    209 
p1 0.7100 
  
Estimated effect size and experimental-group proportion:  
delta -0.1308 (difference) 
p2 0.5792 
 
2.2.4 Study Variables and Measurement  
Two outcomes were defined for the analysis: 
1) Parkinsonism (binary variable):  participants were diagnosed as having parkinsonism  if 
the UPDRS-3 score was greater than or equal to 15 (≥15) (51). Parkinsonism was 
determined at any time point in the study during initial or follow-up examinations. 
2) Quality of Life (continuous variable): the well-being of individuals was rated using the 
PDQ-39 questionnaire which was used to estimate a scaled QoL index score. The index 
score is a summarized standardized measure of the 8 QoL dimensions of the PDQ-39 
questionnaire, such that a higher score indicates poorer QoL (52).  
 
The exposure was cumulative manganese exposure (continuous variable), measured as 
inhalable dust, calculated from reported job titles which were then used to estimate mean 
exposures by homogeneous exposure group (HEG) and time.  
  15 
The matrix estimate of cumulative exposure to manganese was calculated as: 
 
where CEi is the cumulative exposure for worker, i, and Cg is the arithmetic mean concentration 
for HEG, g and tig is the duration of work that worker i spent in HEG, g.  This cumulative 
exposure matrix may also be adjusted to obtain exposures lagged for recent exposure (37), or in 
exploring specific etiologic hypotheses using exposure time windows. 
 
An alternative measure of cumulative manganese exposure was ‘duration of exposure in years’ 
(continuous variable), defined as the total number of years worked in a manganese mine and 
calculated as the difference between job start and end dates in manganese mining. Both types of 
exposure measurements were included in the analysis. 
 
Several additional, potentially confounding variables (demographic, clinical, and behavioural) 
were included in the analyses. These are described in detail in Table 2.  
 
The following variables were analyzed as per the objectives: 
For objective 1, parkinsonism was the outcome variable.  
For objective 2, QoL was the outcome variable.  
For Objective 3, parkinsonism was the outcome variable; and exposure variables were the 
cumulative exposure index and duration of exposure in manganese mining. 
For Objective 4, the outcome variable was QoL; and exposure variables were parkinsonism, 
cumulative exposure index and duration of exposure in manganese mining. 
 iggi tCCE
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Table 2: Potential confounding variables included in the analyses 
# Variable Name Type Description/Definition Variable Coding 
1 Age (years) Continuous Difference between participant’s date of birth 
and study exam date, in years. 
Actual value 
2 Body Mass Index 
(BMI– kg/m2) 
Continuous Weight-to-height ratio, calculated by dividing 
weight (kg) by the square of height (m).  
Actual value 
3 Sex Categorical Male or female. 1 = male 
2 = female 
4 Education Categorical Highest level of education attained, categorized 
into no schooling for uneducated study 
participants, primary for grades 1 – 7, and 
secondary & above for grades 8 – 12 and any 
further education e.g. vocational schools, 
college, university. 
1 = no schooling 
2 = primary 
3 = secondary & 
above 
5 Smoking Categorical Self-reported cigarette smoking status, classified 
as never smoked and ever smoked 
0 = never-smoked 
1 = ex-smoker 
2 = current-smoker 
6 Alcohol Categorical Self-reported alcohol use coded as either yes or 
no. 
0 = no 
1 = yes 
7 Comorbidities  Categorical Self-report of any other sickness or medical 
condition other than the outcome of interest 
(parkinsonism). 
0 = no 
1 = yes 
 
In all models (i.e. objectives 3, 4) potential confounders included were socio-demographic 
factors (age, sex, and education), clinical characteristics (BMI and comorbidities), and 
behavioural variables (smoking status and alcohol use).  
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2.3 Data Management and Data Analysis 
STATA version 13 statistical package (53) was used for data management and statistical 
analysis.  
 
2.3.1 Data Management 
The data management process involved extraction of the study-specific variables from the 
primary dataset. For exploratory data analysis, graphical display and frequency tables were used 
for a logical check for data inconsistencies. Duplicate entries were checked and deleted; validity 
checks were performed; incomplete and incorrect data were identified; and necessary 
modifications were made accordingly, e.g. data imputation. Data imputation involved replacing 
baseline missing data with available data from subsequent participant’s visits. Some of the data 
were re-entered; and some variables were transformed, i.e. new variables were generated, some 
variable formats were changed, and other variables were recoded to meet the objective’s data 
requirements.  
 
2.3.2 Statistical Analysis 
The estimated prevalence of parkinsonism among manganese mine workers was calculated as a 
proportion (objective 1). In addition, socio-demographic and other characteristics were compared 
for those with and without parkinsonism. Categorical variables were reported using frequencies 
(n) and proportions (%), whilst continuous variables were presented as mean (SD); differences 
were tested using the Mann-Whitney test for continuous variables, and Pearson’s Chi-square test 
for categorical variables.  
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QoL was described and compared in those mine workers with and without parkinsonism 
(objective 2). Summary statistics for QoL were described using mean (SD) across all the eight 
QoL dimension sub-scores (mobility, ADL, stigma, emotional well-being, social support, 
cognition, communication, and body discomfort). The Mann-Whitney test was used to compare 
QoL sub-score means.  
 
To determine the association between manganese exposure and parkinsonism the manganese 
mine workers (objective 3), parkinsonism was defined as a binary variable, “no and yes”. 
Predictors of parkinsonism were determined using a logistic regression model adjusted for 
probable confounders. Factors found to be significantly associated with parkinsonism using p-
value less than 0.20 in the univariate analysis, were included in the multivariate logistic 
regression analysis. Manganese exposure (the main exposure variable) and the potential 
confounding variables, age, and smoking status, were included in the final model, regardless of 
their statistical significance.  
 
We performed multiple linear regression analysis to determine the association between 
manganese exposure and QoL among the manganese mine workers (objective 4).  Factors found 
to be significantly associated with QoL based on p-values less than 0.20 in the univariate 
analysis, were included in the multiple linear regression model, adjusting for probable 
confounders. Parkinsonism status (a variable of intrinsic interest), and age (a traditional 
confounder), were included in the final model, regardless of their statistical significance. The full 
multiple linear regression model was fitted, and residual diagnostics were performed to assess if 
model assumptions of normality and constant variance had been violated.  
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Normality plots were used to further assess normality of the QoL outcome variable. Violation of 
the constant variance assumption led to a transformation of the outcome variable. We computed 
margins to measure the effect of the fitted covariates (age, parkinsonism, and presence of 
comorbidities) on QoL. After estimating the margins, using the square root transformed data, we 
squared the estimates (back transformation) to report them in their original form. In addition, the 
variance inflation factor (VIF) was used to assess multi-collinearity in the fitted linear regression 
model, where a VIF with an average mean not considerably larger than 1 was preferred. 
 
For the analyses regarding associations (objectives 3 and 4), the likelihood-ratio test was used in 
model selection.  All final models were assessed for goodness of fit. A marginally significant p-
value was defined as 0.05<p<0.10. For all analyses, unless otherwise specified, a probability 
value of 0.05 was used to define statistical significance. 
 
2.4 Ethical Considerations 
Ethical clearance for both the primary prospective study and secondary analysis was granted by 
the University of the Witwatersrand Human Research Ethics Committee (clearance certificate 
numbers: M091038 and M1611110, respectively: Appendix B). To protect workers’ 
confidentiality, we received unidentified data from the gatekeepers of the database. All 
computerised datasets were safeguarded with a password.  
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CHAPTER 3: RESULTS 
 
A detailed narration of the findings of this study is presented in this chapter. 
 
3.1 Selection of Study Participants for Analysis 
Figure 1 depicts flow chart of exclusion criteria of the study sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All records in miners’ 
prospective study 
(N=426) 
QoL (n=347) 
Exclude: 
Missing QoL 
(n=61) 
Exclude: Missing  
Parkinsonism 
(n=51) 
Valid records after 
duplicates removed 
(n=418) 
Exclude:  
Females 
(n=10) 
Exclude: 
Duplicates 
(n=8) 
Exclude: Missing 
Parkinsonism & 
QoL (n=110) 
Parkinsonism & QoL (n=298) Parkinsonism (n=357) 
Male mine workers’ 
records (n=408) 
 Stratified Statistics and 
Multivariate Analysis 
 Baseline Descriptive 
Statistics 
Figure 1: Exclusion process flow chart 
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A total of 426 participants were in the database of the manganese mine workers that was 
received from the gatekeepers. Eight participants were excluded because they were identified as 
duplicates, thus 418 mine workers remained in the database. Further, participants were excluded 
from analysis for the following reasons: small numbers which would result in spurious results 
and missing information for outcome variables (parkinsonism and QoL). A significant proportion 
of missing values of QoL might have resulted from respondents not completing the self-
administered PDQ-39, health status questionnaire. Whereas, missing parkinsonism data might 
have been a result of the unavailability of a neurologist to perform a neurologic exam which 
includes the UPDRS-3, at any point during the time span of the study. Figure 1 illustrates the 
processes of exclusion, resulting in the following cluster sample sizes which were included in the 
final analysis: i) participants’ baseline descriptive statistics (n=418); ii) parkinsonism data 
(n=357); iii) QoL data (n=347); and iv) parkinsonism and QoL data (n=298).  
 
3.2 Description of Study Participants 
Tables 3 and 4 display the socio–demographic, behavioural, and clinical characteristics of the 
418 manganese mine workers.   The mean age of the participants was 41.5 years (SD=11.9); 
97.6% were male. More than half (57.4%) of the participants had attained secondary level 
education. Less than half (39.7%) reported that they drank alcohol, and 25.1% were current 
smokers. A third (33.7%) of the cohort reported having some physical ailment at their initial 
visit. 
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Table 3: Description of study participants (categorical variables, N=418) 
Characteristic n % 
Sex   
male 408 97.6 
female 10 2.4 
Age   
< 40 194 46.4 
≥ 40 223 53.4 
missing 1 0.2 
Education   
no schooling 35 8.4 
primary 88 21.1 
secondary & above 240 57.4 
missing 55 13.2 
Smoking   
never-smoked 284 67.9 
ex-smoker 23 5.5 
current-smoker 105 25.1 
missing 6 1.4 
Alcohol Use   
no 239 57.2 
yes 166 39.7 
missing 13 3.1 
Comorbidities    
no 262 62.7 
yes 141 33.7 
missing 15 3.6 
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As shown in Table 4, manganese mine workers had an estimated average of 3.7 mg/m3-years 
(SD=5.8) of cumulative manganese exposure at baseline, and a mean duration of manganese 
exposure of 13.5 years (SD=11.7).   
 
Table 4: Description of study participants (continuous variables, N=418) 
Characteristic mean SD 
Cumulative Mn exposure – mg/m3-years 3.7 5.8 
missing - n (%) 2 0.5 
Duration of exposure – years 13.5 11.7 
missing - n (%) 2 0.5 
Age – years 41.5 11.9 
missing - n (%) 1 0.2 
 BMI – kg/m2 25.7 5.7 
missing - n (%) 203 48.6 
    Mn: manganese 
 
3.3 Prevalence of Parkinsonism in Manganese Mine Workers  
The overall prevalence of parkinsonism (UPDRS-3 score ≥15) was 25.4%. Table 5 and Table 6, 
however, display participant’s characteristics by parkinsonism status. In this stratification, 
female participants were excluded because of the very small number (n=10) [Table 3]. The 
resultant prevalence of parkinsonism in active male manganese workers was 29.4%.  
 
There was an inverse, significant relationship between parkinsonism prevalence and miners’ 
education status, i.e. a decreasing prevalence as education increased, p=0.029 [Table 5]. A higher 
prevalence of parkinsonism (36.4%) was noted among participants who reported comorbidities 
as opposed to 25.9% in those without comorbidities, p=0.042. Parkinsonism status did not differ 
significantly with respect to alcohol use (p=0.727) or smoking (p=0.451).  
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Table 5: Number and proportion of participants’ characteristics by parkinsonism status 
Variable 
Parkinsonism No Parkinsonism Total 
P-value n= 105 n= 252 N= 357 
n % n % n 
Sex        
 male 105 29.4 252 70.6 357 - 
Age        
 < 40 35 20.5 136 79.5 171  
 ≥ 40 69 37.3 116 62.7 185 <0.0001* 
 missing 1 100 0 0 1  
Education        
 no schooling 13 43.3 17 56.7 30  
 primary 27 36.5 47 63.5 74  
 secondary & above 52 24.5 160 75.5 212 0.029* 
 missing 13 31.7 28 68.3 41  
Smoking        
 never-smoked 66 27.5 174 72.5 240  
 ex-smoker 6 27.3 16 72.7 22    0.451 
  current-smoker 32 34.4 61 65.6 93  
 missing 1 50 1 50 2  
Alcohol Use        
 no 57 28.2 145 71.8 202  
 yes 44 29.9 103 70.1 147    0.727 
 missing 4 50 4 50 8  
Comorbidities        
 no 58 25.9 166 74.1 224  
 yes 44 36.4 77 63.6 121  0.042* 
 missing 3 25 9 75 12  
*p-values < 0.05 were considered statistically significant 
 
Mean time-weighted cumulative manganese exposure among those with and without 
parkinsonism was 4.1 mg/m3-years (SD=6.2) and 3.5 mg/m3-years (SD=5.8), respectively [Table 
6]. The mean age was 45.3 years (SD=12.8) for mine workers with parkinsonism and 39.6 years 
(SD=11.2) for those without.  
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Mean duration of exposure to manganese was significantly longer in mine workers with 
parkinsonism than in those without, 15 years (SD=12.0) and 12.9 years (SD=11.7), respectively. 
 
Table 6: Description of participants’ characteristics, by parkinsonism status 
Variable 
Parkinsonism No Parkinsonism Total 
P-value 
n= 105 n= 252 N= 357 
n mean (SD) n mean (SD) n mean (SD)  
Cumulative Mn exposure – mg/m3-years 105 4.1 (6.2) 251 3.5 (5.8) 356 3.6 (5.9) 0.1016 
Duration of exposure – years 105 15.0 (12.0) 251 12.9 (11.7) 356 13.5 (11.8)  0.0673* 
Age – years 104 45.3 (12.8) 252 39.6 (11.2) 356 41.2 (11.9)  0.0001* 
BMI – kg/m2 47 24.7 (4.6) 130 26.5 (5.7) 177 26.0 (5.5)  0.0835* 
*p-values < 0.05 were considered statistically significant;  p-values 0.05<p<0.10 were considered marginally significant 
  Mn: manganese 
 
 
3.4 Quality of Life in Manganese Mine Workers 
Table 7 summarizes the PDQ-39 scores in participants with and without parkinsonism. All the 
mean QoL sub-scores, and the total mean PDQ-39 score, were higher in mine workers with 
parkinsonism than in those without. However, these differences between the two groups were 
statistically significant for only the mobility and, emotional well-being sub-scores, and PDQ-39 
total score. The lowest sub-scores were noted for communication (4.5, SD=14.1) in mine 
workers with parkinsonism and stigma (2.6, SD=7.3) in those without parkinsonism. Other 
notable differences in scores between the two groups were for ADL and stigma, although these 
were not statistically significant.   
 
 
  26 
Table 7: Quality of life/health status in manganese mine workers, by parkinsonism status   
*p-values < 0.05 were considered statistically significant; ADL: activities of daily living  
 
Females participants were excluded from this analysis due to the very small number (n=10). 
Likewise, BMI was excluded because it was missing in 48.6% of cases.  
 
3.5 Association between Manganese Exposure and Parkinsonism 
The results of the logistic regression analysis to ascertain the association between manganese 
exposure and parkinsonism are shown in Table 8. 
 
 
 
 
 
QoL DIMENSION 
Parkinsonism No Parkinsonism Total 
P-value 
n= 105 n= 252 N= 357 
n mean (SD) n mean (SD) n mean (SD)  
Total score 89 10.1 (13.0) 209 6.8 (8.4) 298 7.8 (10.1)    0.0112* 
Mobility 89 8.5 (15.8) 208 3.8 (8.6) 297 5.2 (11.4)    0.0013* 
ADL 89 6.1 (14.8) 208 2.7 (6.5) 297 3.7 (9.9) 0.1210 
Emotional 88 16.7 (17.4) 208 12.6 (15.6) 296 13.8 (16.3)    0.0427* 
Stigma 88 5.7 (18.0) 207 2.6 (7.3) 295 3.5 (11.7) 0.3848 
Social support 88 4.8 (13.5) 205 4.1 (12.3) 293 4.3 (12.6) 0.9749 
Cognition 89 12.9 (16.2) 207 11.2 (16.9) 296 11.7 (16.7) 0.1789 
Communication 89 4.5 (14.1) 204 3.8 (9.8) 293 4.0 (11.3) 0.7933 
Body discomfort 89 23.8 (22.7) 204 19.2 (20.4) 293 20.6 (21.2) 0.1111 
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Table 8: Association between manganese exposure and parkinsonism (logistic regression model) 
Predictor Variable 
Unadjusted 
OR 
95% CI P-value 
Adjusted 
OR 
95% CI P-value 
Cumulative Mn exposure – mg/m3-years 1.02 0.98, 1.05 0.395 0.99 0.95, 1.03 0.648 
Age 
  
 
  
 
 
  < 40 reference 
 
reference 
 
  ≥ 40  2.31 1.44, 3.72   0.001* 2.11 1.18, 3.78 0.012* 
Smoking 
  
 
  
 
 
  never-smoked reference 
 
reference 
 
  ex-smoker 0.99 0.37, 2.63 0.982 0.85 0.29, 2.54 0.773 
 
current-smoker 1.38 0.83, 2.31 0.216 1.65 0.92, 2.94 0.092* 
Comorbidities 
  
 
  
 
 
  no reference 
 
reference 
 
 
yes 1.64 1.02, 2.63    0.043* 1.44 0.82, 2.53 0.201 
 OR: Odds Ratio;  CI: Confidence Interval;  Mn: manganese 
*p-values < 0.05 were considered statistically significant;  *p-values 0.05<p<0.10 were considered marginally significant 
 
In both the unadjusted and adjusted analyses, cumulative manganese exposure in South African 
manganese mine workers’ prospective study was not a significant predictor of parkinsonism.  
Table 8 illustrates that age and comorbidities were individually, significantly associated with 
increased odds of parkinsonism. However, after adjusting for probable confounders; only age 
was a strong predictor of parkinsonism, whereas smoking status (current-smoker) was marginally 
significantly associated with parkinsonism.  
The odds of parkinsonism in mine workers 40 years and/or older were 2.11 times (95% CI: 1.18, 
3.78) the odds of parkinsonism in those younger than 40. The odds of parkinsonism in current 
smokers were 1.65 times (95% CI: 0.92, 2.94) the odds of parkinsonism in those who had never 
smoked.  
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We developed the same model using ‘duration of exposure in years’ as an alternative measure of 
manganese exposure. We found that duration of exposure was negatively associated with 
increased risk of parkinsonism (OR=0.97, 95% CI: 0.94, 1.00) [Appendix A, Table 11], contrary 
to earlier findings. 
 
3.6 Association between Manganese Exposure and Quality of Life 
Table 9 presents the summarized results from the multiple linear regression model built to 
evaluate manganese exposure as a predictor of QoL (measured using the square root of scaled 
PDQ-39 total score), adjusted for probable confounders. 
 
Table 9: Association between manganese exposure and QoL (multiple linear regression model) 
Predictor Variable 
Unadjusted Model Adjusted Model 
β 95% CI P-value β 95% CI P-value 
Cumulative Mn exposure – mg/m3-years 0.03 0.00, 0.06 0.070* 0.02 -0.01, 0.05  0.201 
Age 
   
 
  
 
  < 40 reference  reference  
  ≥ 40 0.17 -0.21, 0.56 0.371 -0.48 -0.92, -0.05 0.031* 
Parkinsonism 
   
 
  
 
  no reference  reference  
  yes 0.61 0.19, 1.03 0.005* 0.63 0.20, 1.06 0.004* 
Comorbidities 
   
 
  
 
  no reference  reference  
  yes 0.53 0.14, 0.91 0.007* 0.42 -0.01, 0.84 0.055* 
 QoL: measured using square root of total scaled PDQ-39 score;   Mn: manganese 
*p-values < 0.05 were considered statistically significant;  *p-values 0.05<p<0.10 were considered marginally significant 
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In unadjusted analyses, parkinsonism (β=0.61, p=0.005) and comorbidities (β=0.53, p=0.007) 
strongly predicted increased QoL scores i.e. poorer QoL. Manganese exposure (β=0.03, p=0.070) 
was possibly associated with increased QoL scores.  
After adjustment for socio-demographic, clinical and behavioural characteristics, parkinsonism 
(β=0.63, p=0.004) and age (β= -0.48, p=0.031) were strong predictors of a change in QoL score. 
Parkinsonism predicted poorer QoL and/or health status, and QoL was negatively associated 
with age. Manganese exposure did not significantly predict QoL, and the association between 
QoL and comorbidities was attenuated. 
As summarized in Table 10, we used margins to measure the actual effect of age, parkinsonism, 
and comorbid disease on QoL.  
 
Table 10: Margins estimates for QoL 
Explanatory Variable 
Margins 
estimate 
95% CI 
Back-
transformed 
square root of 
total score 
95% CI 
Age 
     
  < 40 2.51 2.20, 2.83 6.32 4.82, 8.02 
  ≥ 40 2.03 1.76, 2.30 4.12 3.11, 5.27 
Parkinsonism 
     
  no 2.05 1.82, 2.28 4.19 3.30, 5.18 
  yes 2.68 2.32, 3.03 7.17 5.39, 9.21 
Comorbidities 
     
  no 2.08 1.83, 2.33 4.31 3.33, 5.41 
  yes 2.49 2.17, 2.82 6.21 4.69, 7.94 
QoL: measured using square root of total scaled PDQ-39 score;   CI: Confidence Interval 
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In this cohort, participants with parkinsonism and those who had reported any form of comorbid 
disease had significantly higher QoL scores relative to their referent groups (indicated by having 
no overlap in the 95% CI). On average, participants with parkinsonism had QoL scores that were 
2.98 higher than those without. Similarly, the presence of any comorbid disease predicted a 1.90 
higher QoL score relative to the ‘healthy’ participants. 
The effect of age on QoL was evaluated by predicting QoL score estimates at several, specific 
values of age, as presented in Figure 2. We observed an inverse relationship between age and 
QoL i.e. QoL scores decreased (QoL improved) with increasing age. These results are consistent 
with the multiple linear regression model.  
 
 
Figure 2: Predicted margins estimates quantifying the effect of age on QoL 
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We also performed multiple linear regression model with ‘duration of exposure in years’ as the 
primary exposure matrix [Appendix A, Table 12]. The findings of this analysis are consistent 
with our previous results, that is, parkinsonism and age were strong predictors of QoL. 
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CHAPTER 4: DISCUSSION 
 
This chapter provides a detailed discussion on the study’s findings, comparing these with what 
has already been published. It also outlines the study’s strengths and limitations, and ends with 
the conclusion. 
 
4.1 Synopsis of Study Findings 
The aim of the study was to investigate the association between manganese exposure, 
parkinsonism, and quality of life in manganese-exposed mine workers in South Africa. There 
was an inverse, significant relationship between parkinsonism prevalence and miners’ education 
status. Parkinsonism was a strong predictor of QoL. Cumulative manganese exposure, measured 
in mg/m3-years, was not associated with either parkinsonism or QoL; whereas, duration of 
exposure in years, as an alternative measure of manganese exposure, was significantly associated 
with increased risk of parkinsonism. Age was a statistically significant predictor of both 
parkinsonism and QoL.  
 
4.2 Prevalence of Parkinsonism in Manganese Mine Workers 
The estimated prevalence of parkinsonism among the active male manganese workers was 
29.4%. This was high compared to previously published research from two African nations: 
3.7% (4/109) parkinsonism prevalence was reported in a neurology clinic in Ethiopia in 2005 
(54) and a 16.7% (16/96) prevalence was reported in neurology out–patient clinics in Kano state, 
Nigeria in 2012 (26).   
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The latter study considered at least three of the four cardinal features of PD: bradykinesia, 
rigidity, tremors, and gait or postural abnormality in the diagnosis parkinsonism. Contrary to 
expectations, our occupational study had a higher prevalence of parkinsonism compared to these 
neurology patient-based studies.  Differences in methodologies may explain this disparity.   
 
The prevalence of parkinsonism was  high compared to that reported in published studies from 
developed countries, e.g. Racette and co-workers reported prevalence rates of parkinsonism from 
two studies,  2016 and the other in 2012, of 15.2% and 15.6%, respectively, among welders 
occupationally exposed to manganese fumes (24, 51).  
 
Parkinsonism rates have been reported as relatively low in Africa from several general 
population studies (29). Findings from this study reports a higher prevalence. This is a single 
study and is not representative of the general population, thus the results are not generalizable 
beyond manganese miners, but worth taking into consideration for future research and further 
investigations. Nevertheless, previously reported low rates, which are in contradiction to our 
findings, might suggest that parkinsonism is underdiagnosed in Africa, due to lack of expertise 
and limited resources, resulting in the low prevalence rates recorded. Another challenge in Africa 
is the dissemination of neuroscience research findings. Due to lack of funding and information 
access, most research is published in local journals (43) where it might not be accessed by 
international researchers. This could account for the disparities in the reported prevalence rates 
of parkinsonism as there is limited information internationally.  
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4.3 Quality of Life in South African Manganese Mine Workers with Parkinsonism 
Similar to one previous occupational–epidemiological study (30), QoL sub-scores and PDQ-39 
total score means were higher in workers with parkinsonism, relative to those without, 
confirming findings from other studies (30) that workers with parkinsonism tend to experience 
poorer health status than those without parkinsonism. This finding, coupled with the reported 
high prevalence of parkinsonism in our analysis, might have implications for early diagnosis, 
initiation to therapy and management of parkinsonism in the workplace to improve workers’ 
QoL, or at least slow down the progressive deterioration of an individuals’ health status.  
 
 The QoL scores for emotional well-being and mobility were significantly higher than the 
remaining QoL sub-domains. Motor deficits can limit the performance of individual’s daily 
activities, whilst emotional instability can result in depression and other psychological and/or 
psychiatric disorders (28). Collectively or alone, these might affect job performance, increasing 
absenteeism, reducing productivity, and increasing the risk of injury in the workplace (30). This 
finding warrants further research on the neuropsychological impact of chronic exposure to 
manganese in healthy workers.   
 
4.4 Association between Manganese Exposure and Parkinsonism 
We found no evidence of a monotonic dose-response relationship between estimated cumulative 
manganese exposure and parkinsonism, despite the high prevalence of parkinsonism. Several 
epidemiological studies, mostly among welders, have evaluated the effects of manganese 
exposure in exposed individuals, and  have found a significant association between occupational 
manganese exposure and parkinsonism (24, 45).  
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The lack of a monotonic dose–response relationship between parkinsonism and manganese mine 
exposure, in our analysis, may be due to the healthy worker survivor effect or a nonlinear 
relationship or that manganese levels were relatively low to induce parkinsonism. On average, 
manganese mine workers were exposed to an estimated 3.7 mg/m3-years (SD=5.8) of cumulative 
manganese, with a median of 1.8 mg/m3-years (IQR 0.7 – 3.6). Differing methodologies used in 
the diagnosis of parkinsonism and assessment of manganese exposure may also explain our 
findings. In the same analysis, duration of exposure was negatively associated with parkinsonism 
possibly due to a collinearity effect between duration of exposure and age.  
 
The discordance in our findings emphasize the need for a consistent measurement approach of 
the manganese exposure matrix, to make research findings comparable across studies. Either 
‘duration of exposure’ or the ‘cumulative exposure matrix’ is an inappropriate estimate of 
manganese exposure.  
 
Being 40 years or older was most predictive of having parkinsonism. Several researchers have 
posited that older age is an important determinant of parkinsonism (26, 44). PD is very rare in 
individuals younger than 40 years (29, 55).  
 
In some previous studies, smoking has been found to be protective against PD (negative 
association) (56, 57), yet we found a marginally significant positive association between 
smoking and parkinsonism in our study – suggesting that smoking might have no effect on 
parkinsonism induced by toxins, as opposed to induced PD and smoking.  
 
  36 
4.5 Quality of Life Predictors 
In this analysis, manganese exposure was not predictive of any change in individuals’ QoL or 
health status in the manganese miners included in the primary prospective study. The association 
between manganese exposure and QoL has not been previously evaluated, but has rather  been 
deduced from scientific reviews and reports on the neurotoxic symptoms that are usually 
displayed by chronically exposed individuals (58).  
 
Increasing age was associated with improved QoL. This might be true of the general population, 
but contradicts plausible evidence of a negative association between age and QoL among PD 
patients (59, 60). This finding is surprising and to our best knowledge, this has not been 
previously reported. It is difficult to explain this finding, although the healthy worker effect is a 
possible reason for the inverse association between age and QoL.  
 
We also found a strong association between parkinsonism and QoL. This supports Harris and 
colleagues’  research where they reported elevated PDQ-39 total scores in parkinsonian welders 
compared to a referent group (30). Patients with parkinsonism frequently experience motor 
deficits which contribute to a decline in physical functional status, limiting work ability and 
performance of daily activities and impacting physical health and social interaction (28, 30). In 
the workplace, these, could have significant repercussions for worker safety and performance.  
Regression modelling using ‘duration of exposure’ or the ‘cumulative exposure matrix’ yielded 
the similar results, that is, parkinsonism and age were strong predictors of QoL. 
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4.6 Limitations 
The prevalence of parkinsonism might be underestimated in this cohort due to the healthy worker 
survivor effect. Limitations with regard to the available information was expected, since data 
were not collected to answer the research question addressed in this report but, rather, were 
collected to determine if there was progression of parkinsonism in a cohort of manganese-
exposed mine workers. 
 
Although the primary study was conducted longitudinally, data were analyzed at baseline only 
due to missing data in subsequent visits. The cross-sectional nature of this study design means 
we are unable to infer causality, i.e. exposure and outcome were simultaneously assessed; thus, it 
is difficult to establish the temporal relationship between exposure and outcomes.  
 
This study provides compelling evidence that parkinsonism in manganese miners is associated 
with abnormalities in QoL, but we cannot exclude the possibility that non-specific motor 
symptoms, not related to parkinsonism, might also be contributing to the QoL dysfunction. 
 
We relied on an exposure matrix to indirectly estimate manganese exposure levels which 
potentially introduced exposure misclassification. The same matrix might be an inaccurate 
measure of manganese exposure in this group of mine workers, as it was developed in a different 
group. The matrix was computed using the mean rather than the median exposure; the median is 
an appropriate measure of central tendency for hygiene data because these are typically right 
skewed. 
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4.7 Strengths 
Known confounders were considered by adjusting exposure effects using multivariate analysis.   
The use of (i) highly qualified personnel (e.g. movement disorders specialist) for clinical 
examination, thus disease misclassification unlikely and (ii) valid, specific, and reliable data 
collection instruments in the primary study, further strengthened this analysis.  
 
4.8 Conclusion 
The prevalence of parkinsonism in this group of mine workers was very high. Manganese mine 
workers with parkinsonism had poorer QoL or health status than those without parkinsonism. 
The results from the multivariate analysis, that parkinsonism strongly predicted QoL, 
corroborates this finding. These results support the hypothesis that parkinsonism in manganese–
exposed workers is associated with poorer QoL, consistent with observations in other patients 
with parkinsonism.  
 
Although an association between parkinsonism and manganese exposure was not demonstrated 
in this analysis, a parkinsonian syndrome associated with exposure to high levels of manganese 
has been previously described.  Our finding does not preclude the possibility that chronic 
exposure to manganese, as occurs in mining, can lead to parkinsonism. South Africa’s time-
weighted average OEL for manganese dust and compounds is 5 mg/m3. This threshold limit 
value has not been tested with regard to associated health effects in South Africa or the African 
region.  
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APPENDIX A: Complementary Study Tables 
 
Table 11: Association between duration of exposure and parkinsonism (logistic regression model) 
Predictor Variable 
Unadjusted 
OR 
95% CI P-value 
Adjusted 
OR 
95% CI P-value 
Duration of exposure – years 1.01 1.00, 1.03 0.133 0.97 0.94, 1.00 0.041* 
Age – years  1.04 1.02, 1.06  <0.0001* 1.06 1.02, 1.09 0.001* 
Smoking          
  never-smoked reference  reference  
  ex-smoker 0.99 0.37, 2.63 0.982 0.90 0.30, 2.65  0.844 
 current-smoker 1.38 0.83, 2.31 0.216 1.65 0.92, 2.97 0.094* 
Comorbidities          
  no reference  reference  
  yes 1.64 1.02, 2.63 0.043* 1.48 0.82, 2.66  0.190 
OR: Odds Ratio;  CI: Confidence Interval;  *p-values < 0.05 were considered statistically significant;                
*p-values 0.05<p<0.10 were considered marginally significant 
 
Table 12: Association between duration of exposure and QoL (multiple linear regression model) 
Predictor Variable 
Unadjusted Model Adjusted Model 
β 95% CI P-value β 95% CI P-value 
Duration of exposure – years 0.00 -0.01, 0.02 0.604 0.01 -0.01, 0.03   0.385 
Age 
 
      
 
< 40 reference 
 
reference 
 
 
≥ 40 0.17 -0.21, 0.56 0.371 -0.56 -1.10, -0.01 0.045* 
Parkinsonism 
 
      
 
no reference 
 
reference 
 
 
yes 0.61 0.19, 1.03 0.005* 0.63 0.21, 1.06 0.004* 
Comorbidities 
 
      
 
no reference 
 
reference 
 
 
yes 0.53 0.14, 0.91 0.007* 0.41 -0.02, 0.84   0.063 
QoL: measured using square root of total scaled PDQ-39 score; *p-values < 0.05 were considered statistically significant; 
*p-values 0.05<p<0.10 were considered marginally significant
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